$MJN (Mead Johnson Nutrition Company)

Glenview, Illinois-based pediatric nutrition company $MJN said that its BoD has declared a regular quarterly dividend of $0.4125 per share for the quarter ending March 31, 2016. The dividend will be paid on April 1, 2016, to shareholders of record at close of business on March 14, 2016.

$MJN completed its merger with Reckitt Benckiser Group plc (RB). As a result of the transaction, $MJN's common stock is no longer traded on the NYSE, effective June 15, 2017. Mead Johnson is now a division of RB, adding its globally-recognized brands, including Enfa and Nutramigen, to RB's powerful consumer health portfolio.

$MJN announced that the final regulatory approval has been
received in order to complete its acquisition by Reckitt Benckiser Group plc.
The transaction is expected to close on June 15, 2017, subject to the
satisfaction of customary closing conditions.

$MJN BoD declared a regular quarterly dividend of $0.4125 per share for the quarter ending June 30, 2017. The dividend will be paid on July 5, 2017, to shareholders of record at close of business on June 20, 2017.

$MJN stockholders approved the company being acquired by Reckitt Benckiser Group plc (RB). Shareholders of RB also approved the transaction. Under the terms of the agreement between $MJN and Reckitt Benckiser, stockholders of $MJN will receive $90 in cash for each share upon closing of the transaction, and $MJN will become a new division of RB.

$MJN to be acquired by Reckitt Benckiser Group Plc in an all-cash transaction valued at approx. $17.9Bil including debt. The transaction, that is subjected to approvals from shareholders of both companies, is expected to be finalized in 3Q17.

Pediatric nutrition company $MJN declared a dividend of $0.4125 per share for the quarter ending March 31, 2017. The dividend will be paid on April 3, 2017, to shareholders of record as of March 13, 2017.

$MJN has reached an agreement to acquire spray drying and
finishing capabilities in Australia from Bega Cheese Limited, an Australian dairy
product company. The transaction is expected to close in 2Q17.

$MJN said the transaction has been unanimously approved by its BoD. Closing of the transaction is subject to customary conditions, including approval by shareholders of both $MJN and Reckitt Benckiser Group plc and regulatory approvals, and is expected to occur during 3Q17.

$MJN announced that it has reached an agreement to be acquired by Reckitt Benckiser Group plc (RB), a consumer health and hygiene company. Consequently, $MJN will become a new division of RB with its Enfamil and Nutramigen brands. RB has agreed to pay $90 cash for each share of $MJN common stock valued at approx. $17.9Bil, including net debt.

$MJN confirmed that it is in discussions with Reckitt Benckiser plc with respect to its proposal to acquire the outstanding shares of $MJN for $90 per share in cash. This is in response to media reports and a subsequent statement released by Reckitt Benckiser.

$MJN expects 2017 net sales to be down 3% and breakeven compared to 2016 on a reported basis and in down 1% and up 2% range on constant dollar basis. Sales on a reported basis will be impacted by future foreign exchange changes which cannot be estimated.

$MJN reported a rise in 4Q16 earnings driven by lower operating expenses despite a decline in sales. Net income rose to $167.8MM or $0.91 per share from $128MM or $0.67 per share last year. Net sales fell to $901.6MM from $967MM. Non-GAAP EPS was $0.78, unchanged from a year ago.

$MJN said its BoD declared a regular quarterly dividend of
$0.4125 per share for the quarter ending December 31, 2016. The dividend will
be paid on January 6, 2017, to shareholders of record on Friday, December 23,
2016.

For 2016, $MJN expects gross margin to be up 64.5%, while fuel for growth savings are expected to be at the high end of the $75-80MM range. The ForEx impact is expected to be approx. $0.30 per share from the company's previous guidance of $0.35 per share.

In Latin America, $MJN stated segment performance continues to be heavily impacted by the suspension of sales to Venezuela. These shipments all but seized at the end of 2015. Excluding this impact, sales in Latin America grew 5% in constant dollars over 3Q15. Including the impact of Venezuela, constant dollar sales were in line with the prior year.

In the North America and Europe segment, $MJN said the results were mixed in 3Q16. Market share gains in Canada and Europe resulting in strong sales growth offset a disappointing quarter in the US. Net sales were in line with 3Q15 on a constant dollar basis. The segment benefited from a 5% pricing benefit, offset by lower volumes in the US.

With regard to targeted OpEx reductions, year-to-date 2016 $MJN has delivered $67MM in savings and has achieved approx. 85% of its annual target. SG&A expenses in 3Q16 were almost $20MM lower than a year earlier.

On a net sales basis, $MJN's three geographic segments delivered sales in line with last year. This is an improvement over the previous two quarters. Excluding the effect of suspended shipments to Venezuela, net sales grew 1% in 3Q16 over the prior year quarter.